LONDON: OXB (LSE: OXB), a leading global cell and gene therapy contract development and manufacturing organization (CDMO), has acquired the remaining 10% stake in its U.S. subsidiary, OXB US LLC, from Q32 Bio, Inc., securing full ownership of the facility. The move, finalized after OXB’s U.S. subsidiary exercised a prearranged call option in March,…